Coriell Institute for Medical Research
Coriell Institute of Medical Research
  • Request a Quote
  • Donate
  • Login
  • View Cart
Sample Catalog | Custom Services | Core Facilities | Genomic Data Search
  • Biobank
    • NIGMS
    • NINDS
    • NIA
    • NHGRI
    • NEI
    • Allen Cell Collection
    • Rett Syndrome iPSC Collection
    • Autism Research Resource
    • HD Community Biorepository
    • CDC Cell and DNA
    • J. Craig Venter Institute
    • Orphan Disease Center Collection
    • All Biobanks
  • Research
    • Overview
    • Meet Our Scientists
      • Our Faculty
      • Our Scientific Staff
    • Camden Cancer Research Center
    • Epigenetic Therapies SPORE
    • Core Facilities
    • Epigenomics
    • Camden Opioid Research Initiative (CORI)
    • The Issa & Jelinek Lab
    • The Jian Huang Lab
    • The Luke Chen Lab
      • The Lab
      • The Team
      • Publications
    • The Scheinfeldt Lab
    • The Shumei Song Lab
    • The Nora Engel Lab
      • The Lab
      • The Team
      • Publications
    • Publications
  • Services
    • Overview
    • Biobanking Services
      • Core Services
      • Project Management
      • Research Support Services
      • Sample Cataloging
      • Sample Collection Kits
      • Sample Data Management
      • Sample Distribution
      • Sample Management
      • Sample Procurement
      • Sample Storage
    • Bioinformatics and Biostatistics Services
    • Cellular and Molecular Services
      • Biomarker Research Solutions
      • Cell Culture
      • Nucleic Acid Isolation and Quality Control
    • Clinical Trial Support
      • Overview
      • Sample Collection
      • Data Management
      • Sample Processing and QC
      • Storage and Distribution
      • Biomarker Services
      • Data Analaysis
    • Core Facilties
      • Overview
      • Animal and Xenograft
      • Bioinformatics and Biostatistics
      • Cell Imaging
      • CRISPR Gene Engineering
      • Flow Cytometry and Cell Sorting
      • Genomics and Epigenomics
      • iPSC - Induced Pluripotent Stem Cells
      • Organoids
    • Coriell Marketplace
    • Genomic, Epigenomic and Multiomics Services
    • Stem Cells and iPSC Services
      • Core Services
      • Reprogramming
      • Characterization and Quality Control
      • Differentiated Cell Lines
      • iPSC-Derived Organoids
      • iPSC Expansion
      • iPSC Gene Editing
  • Ordering
    • Stem Cells
    • Cell Lines
    • DNA and RNA
    • Featured Products
      • FFPE
      • HMW DNA
    • Genomic Data Search
    • Search by Catalog ID
    • Help
      • Create Account
      • Order Online
      • Ordering FAQ
      • FAQs/Culture Instructions
      • Reference Materials
        • Biobanks
        • NIGMS Repository
        • NHGRI Repository
        • NINDS Repository
        • NIA Repository
        • NIST
        • GeT-RM
      • Secondary Distribution Policies
      • MTA Assurance Form
      • Shipment Policy
      • Contact Customer Service
  • About Us
    • Our History
    • Meet Our Team
    • Meet Our Board
    • Education
      • Science Fair
      • Summer Experience
      • Outreach
      • Research Program Internship
    • Press Room
      • Press Releases
      • Coriell Blog
      • Annual Report
    • Careers
      • Working at Coriell
    • Giving
      • Donate
      • Giving FAQ
    • Contact Us
    • Legal Notice
  • Login View Cart
search submit
GM10810 LCL from B-Lymphocyte

Description:

ADENINE PHOSPHORIBOSYLTRANSFERASE DEFICIENCY; APRTD
ADENINE PHOSPHORIBOSYLTRANSFERASE; APRT 2,8-@DIHYDROXYADENINE UROLITHIASIS, INCLUDED

Affected:

Yes

Sex:

Male

Age:

50 YR (At Sampling)

  • Overview
  • Characterizations
  • Phenotypic Data
  • Publications
  • External Links
  • Culture Protocols

Overview

back to top
Repository NIGMS Human Genetic Cell Repository
Subcollection Heritable Diseases
Class Disorders of Nucleotide and Nucleic Acid Metabolism
Alternate IDs GM17055 [ADENINE PHOSPHORIBOSYLTRANSFERASE DEFICIENCY; APRTD]
Biopsy Source Peripheral vein
Cell Type B-Lymphocyte
Tissue Type Blood
Transformant Epstein-Barr Virus
Sample Source LCL from B-Lymphocyte
Race Asian
Ethnicity JAPANESE
Relation to Proband proband
Confirmation Biochemical characterization before cell line submission to CCR
Species Homo sapiens
Common Name Human
Remarks Japanese; type II APRT deficiency; 2,8dihydroxyadenine urolithiasis with homozygosity for a mutant form of APRT; approximately 25% of normal APRT activity in lymphoid culture

Characterizations

back to top
IDENTIFICATION OF SPECIES OF ORIGIN Species of Origin Confirmed by Nucleoside Phosphorylase, Glucose-6-Phosphate Dehydrogenase, and Lactate Dehydrogenase Isoenzyme Electrophoresis
 
adenine phosphoribosyltransferase According to the submitter, biochemical test results for this subject showed decreased enzyme activity. EC Number: 2.4.2.7; 25% activity.
 
Gene APRT
Chromosomal Location 16q24
Allelic Variant 1 102600.0003; APRT DEFICIENCY, JAPANESE TYPE
Identified Mutation MET136THR; Hidaka et al. (1988) identified a T-to-C substitution in exon 5 at position 2069, giving rise to substitution of threonine for methionine at position 136 in the Japanese-type APRT deficiency. The enzyme showed abnormal kinetics and activity that was less than 10.3% of normal. Six other Japanese homozygotes carried the same mutation on at least 1 allele. In the Japanese type of APRT deficiency, Kamatani et al. (1989) took advantage of the fact that the only methionine residue in normal APRT (at position 136) has been changed to threonine. By means of specific cleavage of the peptide at the methionine residue with cyanogen bromide (BrCN), they could distinguish normal from mutant proteins. Kamatani et al. (1989) found that 79% of all Japanese patients with this disease and more than half of the world's patients have this particular mutation. Kamatani et al. (1990) found that 24 of 39 Japanese 2,8-dihydroxyadenine urolithiasis patients had only APRT*J alleles. They found that normal alleles occur in 4 major haplotypes, whereas all APRT*J alleles occurred in only 2. They interpreted this as meaning that all APRT*J alleles had a single origin and that this mutant sequence has been maintained for a long time, as reflected in the frequency of the recombinant alleles. Sahota et al. (1991) described DHA-lithiasis in a patient heterozygous for the Japanese mutation. Lithiasis had previously been observed only in homozygotes. The polyamine pathway is thought to be the major source of endogenous adenine in the human. Whether increased polyamine synthesis can lead to increased adenine production, enhancer to DHA-lithiasis in an APRT heterozygote, remains to be determined. Among 141 defective APRT alleles from 72 different Japanese families, Kamatani et al. (1992) found the met136-to-thr mutation in 96 (68%); 30 (21%) and 10 (7%) had the TGG-to-TGA nonsense mutation at codon 98 (102600.0005) and duplication of a 4-bp sequence in exon 3 (102600.0006), respectively. Kamatani et al. (1996) noted that the APRT*J mutation is distributed nearly uniformly on the 4 main islands of Japan and Okinawa, suggesting a very early origin. Among 955 random Japanese blood samples, 7 (0.73%) were heterozygous for the APRT*J mutation. None of 231 Taiwanese samples contained heterozygotes for this mutation, whereas 2 (0.53%) of 356 Korean samples were heterozygous. Since the APRT*J mutation was found in Koreans and Okinawans who shared ancestors only before the Yayoi era (third century B.C. to third century A.D.), the origin of the APRT*J mutation predates 300 B.C.
 
Gene APRT
Chromosomal Location 16q24
Allelic Variant 2 102600.0003; APRT DEFICIENCY, JAPANESE TYPE
Identified Mutation MET136THR; Hidaka et al. (1988) identified a T-to-C substitution in exon 5 at position 2069, giving rise to substitution of threonine for methionine at position 136 in the Japanese-type APRT deficiency. The enzyme showed abnormal kinetics and activity that was less than 10.3% of normal. Six other Japanese homozygotes carried the same mutation on at least 1 allele. In the Japanese type of APRT deficiency, Kamatani et al. (1989) took advantage of the fact that the only methionine residue in normal APRT (at position 136) has been changed to threonine. By means of specific cleavage of the peptide at the methionine residue with cyanogen bromide (BrCN), they could distinguish normal from mutant proteins. Kamatani et al. (1989) found that 79% of all Japanese patients with this disease and more than half of the world's patients have this particular mutation. Kamatani et al. (1990) found that 24 of 39 Japanese 2,8-dihydroxyadenine urolithiasis patients had only APRT*J alleles. They found that normal alleles occur in 4 major haplotypes, whereas all APRT*J alleles occurred in only 2. They interpreted this as meaning that all APRT*J alleles had a single origin and that this mutant sequence has been maintained for a long time, as reflected in the frequency of the recombinant alleles. Sahota et al. (1991) described DHA-lithiasis in a patient heterozygous for the Japanese mutation. Lithiasis had previously been observed only in homozygotes. The polyamine pathway is thought to be the major source of endogenous adenine in the human. Whether increased polyamine synthesis can lead to increased adenine production, enhancer to DHA-lithiasis in an APRT heterozygote, remains to be determined. Among 141 defective APRT alleles from 72 different Japanese families, Kamatani et al. (1992) found the met136-to-thr mutation in 96 (68%); 30 (21%) and 10 (7%) had the TGG-to-TGA nonsense mutation at codon 98 (102600.0005) and duplication of a 4-bp sequence in exon 3 (102600.0006), respectively. Kamatani et al. (1996) noted that the APRT*J mutation is distributed nearly uniformly on the 4 main islands of Japan and Okinawa, suggesting a very early origin. Among 955 random Japanese blood samples, 7 (0.73%) were heterozygous for the APRT*J mutation. None of 231 Taiwanese samples contained heterozygotes for this mutation, whereas 2 (0.53%) of 356 Korean samples were heterozygous. Since the APRT*J mutation was found in Koreans and Okinawans who shared ancestors only before the Yayoi era (third century B.C. to third century A.D.), the origin of the APRT*J mutation predates 300 B.C.

Phenotypic Data

back to top
Remarks Japanese; type II APRT deficiency; 2,8dihydroxyadenine urolithiasis with homozygosity for a mutant form of APRT; approximately 25% of normal APRT activity in lymphoid culture

Publications

back to top
Lin YW, Thi DA, Kuo PL, Hsu CC, Huang BD, Yu YH, Vogt PH, Krause W, Ferlin A, Foresta C, Bienvenu T, Schempp W, Yen PH, Polymorphisms associated with the DAZ genes on the human Y chromosome Genomics86:431-8 2005
PubMed ID: 16085382

External Links

back to top
dbSNP dbSNP ID: 11432
Gene Cards APRT
Gene Ontology GO:0003999 adenine phosphoribosyltransferase activity
GO:0006166 purine ribonucleoside salvage
GO:0006168 adenine salvage
GO:0009116 nucleoside metabolism
GO:0016757 transferase activity, transferring glycosyl groups
NCBI Gene Gene ID:353
NCBI GTR 102600 ADENINE PHOSPHORIBOSYLTRANSFERASE; APRT
614723 ADENINE PHOSPHORIBOSYLTRANSFERASE DEFICIENCY; APRTD
OMIM 102600 ADENINE PHOSPHORIBOSYLTRANSFERASE; APRT
614723 ADENINE PHOSPHORIBOSYLTRANSFERASE DEFICIENCY; APRTD

Culture Protocols

back to top
Split Ratio 1:3
Temperature 37 C
Percent CO2 5%
Medium Roswell Park Memorial Institute Medium 1640 with 2mM L-glutamine or equivalent
Serum 15% fetal bovine serum Not Inactivated
Substrate None specified
Subcultivation Method dilution - add fresh medium
Supplement -
Pricing
International/Commercial/For-profit:
$373.00USD
U.S. Academic/Non-profit/Government:
$216.00USD
Add to Cart
How to Order
  • Ordering Instructions
  • MTA / Assurance Form
  • Statement of Research Intent Form
Related Products
Same Subject
  • NA10810 - DNA
Miscellaneous
  • DNA on Demand
  • Custom Services

Our mission is to prevent and cure disease through biomedical research.

CONTACT US

CUSTOMER SERVICE
customerservice@coriell.org (800) 752-3805 • (856) 757-4848
Subscribe to our newsletter here

Coriell Institute for Medical Research
403 Haddon Avenue Camden, NJ 08103, USA (856) 966-7377

Ⓒ 2025 Coriell Institute. All rights reserved.

  • Facebook
  • Linkedin
  • Youtube